Tethys Bioscience, Inc.

Founded 2002

Emeryville, United States 20 employees Debt Financing Total: $75.40M Biotechnology, Health Care

Tethys Bioscience, Inc. was established in 2002 with the mission to create and commercialize innovative blood tests to assess imminent disease risk. Their focus was on reducing the burden of preventable chronic diseases by preempting their development. The company's flagship product, PreDx® Diabetes Risk Score, was a fasting blood test that provided an unprecedented level of risk stratification for patients at risk for type 2 diabetes. Recent studies showed that a decrease in PreDx DRS correlated with a decreased risk of diabetes years later. Tethys aimed to build a sustainable cardiometabolic diagnostics business by expanding its commercial infrastructure and establishing partnerships to increase physician use. However, the company closed its doors in 2014, and its assets were acquired by Human Diagnostics Labs. The last recorded investment was a $12.00M Debt Financing investment on 01 January 2012, led by Armentum Partners. Tethys Bioscience operated in the Biotechnology and Health Care industries and was headquartered in the United States.

Funding Stage	Amount	Investors	Lead Investors	Date
Debt Financing	$12.00M	1	Armentum Partners	01 Jan 2012
Debt Financing	$10.00M	2	Silicon Valley Bank, Oxford Finance LLC	21 Jul 2010
Venture Round	$23.00M	2	Greenspring Associates, Paul Capital	21 Jul 2010
Series D	$25.00M	5	Kleiner Perkins, Mohr Davidow Ventures +3	09 Nov 2009
Series C	Undisclosed	4	Kleiner Perkins, Greenspring Associates +2	10 Jan 2008
Series A	$5.40M	1	Mohr Davidow Ventures	31 Oct 2005

Funding Stage

Amount

Investors

Lead Investors

Date

Debt Financing

$12.00M

Armentum Partners

01 Jan 2012

Debt Financing

$10.00M

Silicon Valley Bank, Oxford Finance LLC

21 Jul 2010

Venture Round

$23.00M

Greenspring Associates, Paul Capital

21 Jul 2010

Series D

$25.00M

Kleiner Perkins, Mohr Davidow Ventures +3

09 Nov 2009

Series C

Undisclosed

Kleiner Perkins, Greenspring Associates +2

10 Jan 2008

Series A

$5.40M

Mohr Davidow Ventures

31 Oct 2005

FAQ About Tethys Bioscience, Inc.

Our Mission To create and commercialize innovative blood tests that accurately assess imminent disease risk, enabling healthcare providers to preempt the onset of chronic cardiometabolic conditions by focusing healthcare resources on those patients who will benefit the most from early and aggressive...

Tethys Bioscience, Inc. was founded in 2002.

Tethys Bioscience, Inc. is headquartered in Emeryville, United States.

Tethys Bioscience, Inc. operates in Biotechnology and Health Care. Its work centres on blood tests, disease risk assessment, chronic diseases and cardiometabolic conditions.

Tethys Bioscience, Inc. has approximately 20 employees.

Tethys Bioscience, Inc. has completed 6 funding rounds, raising a total of $75.40M. The latest funding stage is Debt Financing.

Top alternatives and competitors to Tethys Bioscience, Inc. include ProterixBio, LungLife AI, Carenostics, Renalytix, InterVenn Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Tethys Bioscience, Inc. and ProterixBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Tethys Bioscience, Inc.

Funding Rounds & Investors (6)

Tethys Bioscience, Inc. Alternatives & Competitors

FAQ About Tethys Bioscience, Inc.